PRKACG

Across TCGA pan-cancer cohorts, PRKACG Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRKACG data layer compared with 13 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PRKACG Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated PRKACG expression acts as an unfavorable survival marker, although some lineages such as OV show a favorable association.

OV, KIRP, and SCLC are the cancer types where PRKACG Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.509	0.160	.025	18	view →
KIRP	DFS	Median	II,III,IV	0.037	0.783	<.001	12	view →
SCLC	OS	Median	III,IV	0.192	0.635	.019	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRKACG–OV (DFS)

Open the OV breakdown →